41. 巨細胞性動脈炎 Giant cell arteritis Clinical trials / Disease details

臨床試験数 : 131 / 薬物数 : 139 - (DrugBank : 36) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 125

5 trials found

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-004809-31-DK (EUCTR)	18/11/2021	01/08/2021	Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA).	A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ...	giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKINU ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Australia;Denmark;S ...
2	EUCTR2020-004809-31-NO (EUCTR)	16/11/2021	28/06/2021	Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA).	A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ...	giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe Product Name: Cosentyx Product ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;S ...
3	EUCTR2020-004809-31-DE (EUCTR)	19/10/2021	12/07/2021	Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA).	A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ...	giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKINU ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;S ...
4	EUCTR2020-004809-31-PT (EUCTR)	13/10/2021	07/07/2021	Study of efficacy and safety of secukinumab 300 mg and 150 mg in patients with giant cell arteritis ...	A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ...	giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKINU ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	348	Phase 3	Russian Federation;United States;Czechia;Portugal;Sweden;Netherlands;Brazil;Guatemala;Poland;France; ...
5	EUCTR2020-004809-31-FI (EUCTR)	05/10/2021	16/07/2021	Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA).	A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ...	giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKINU ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;S ...

First Previous1Next Last